WO2009083530A2 - Fluoride processing method - Google Patents

Fluoride processing method Download PDF

Info

Publication number
WO2009083530A2
WO2009083530A2 PCT/EP2008/068155 EP2008068155W WO2009083530A2 WO 2009083530 A2 WO2009083530 A2 WO 2009083530A2 EP 2008068155 W EP2008068155 W EP 2008068155W WO 2009083530 A2 WO2009083530 A2 WO 2009083530A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
solution
cryptand
fluoride
water
Prior art date
Application number
PCT/EP2008/068155
Other languages
French (fr)
Other versions
WO2009083530A3 (en
Inventor
Alexander Jackson
Rajiv Bhalla
Original Assignee
Ge Healthcare Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP08868276A priority Critical patent/EP2238074A2/en
Priority to JP2010541049A priority patent/JP5705547B2/en
Priority to MX2010007398A priority patent/MX2010007398A/en
Priority to US12/810,893 priority patent/US8980221B2/en
Priority to RU2010126591/04A priority patent/RU2475448C2/en
Priority to CN200880123900.8A priority patent/CN102026913B/en
Application filed by Ge Healthcare Limited filed Critical Ge Healthcare Limited
Priority to AU2008342628A priority patent/AU2008342628B2/en
Priority to CA2710799A priority patent/CA2710799C/en
Priority to BRPI0821681-9A priority patent/BRPI0821681A2/en
Publication of WO2009083530A2 publication Critical patent/WO2009083530A2/en
Publication of WO2009083530A3 publication Critical patent/WO2009083530A3/en
Priority to US14/659,414 priority patent/US20150191477A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0093Microreactors, e.g. miniaturised or microfabricated reactors
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B9/00General methods of preparing halides
    • C01B9/08Fluorides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00781Aspects relating to microreactors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The invention relates to methods for processing [18F]-fluoride target water using a solid-support bound Cryptand of formula (I) and to apparatus for performing such methods. The resultant [18F]-fluoride is useful for preparation of radiopharmaceuticals by nucleophilic fluorination, specifically for use in Positron Emission Tomography (PET).

Description

FLUORIDE PROCESSING METHOD
The present invention relates to methods for processing [18F]-fluoride target water, and to apparatus for performing such methods. The resultant [18F]-fluoride is useful for preparation of radiopharmaceuticals by nucleophilic fluorination, specifically for use in Positron Emission Tomography (PET).
Fluorine-18 is obtained by a variety of nuclear reactions from both particle accelerators and nuclear reactors, and can be produced at specific activities approaching 1.71 xl09Ci/mmol. The half-life of fluorine-18 is 109.7 minutes, relatively long in comparison with other commonly used radioisotopes but still imposing time constraints on processes for preparing 18F-labelled radiopharmaceuticals.
Most fluorine-18 is produced by irradiation of an [18O]oxygen gas target by the nuclear reaction 18O(p,n)18F, and isolated as [18F]fluoride ion in aqueous solution. In aqueous form, [18F]fluoride can be relatively unreactive, and so certain steps are routinely performed to provide a reactive nucleophilic [18F]fluoride reagent.
Following irradiation, a positively charged counterion is added, most commonly potassium complexed by a cryptand such as Kryptofix 222 (4,7,13,16, 21,24-hexaoxa-l, 10-diazabicyclo [8,8,8] hexacosan), or alternatively, cesium, rubidium, or a tetralkylammonium salt. This is commonly achieved by passing the [18F] fluoride target water (typically in volumes of 1 to 5mL) through an anion exchange resin and eluting with an aqueous organic solution (typically in a volume of 0.3 to ImL) of the counterion, for example, with a potassium carbonate/Kryptofix solution in water/acetonitrile. Secondly, the solution is dried, commonly by azeotroping in the presence of a low- boiling solvent such as acetonitrile. Automated radiosynthesis apparatus routinely include such a drying step, typically lasting 9 minutes in the case of [18F]FDG synthesis on Tracerlab MX (GE Healthcare). The compound to be labelled (dissolved in an organic solvent suitable for performing the subsequent radiosynthesis, usually an aprotic solvent such as acetonitrile, dimethylsulphoxide or dimethylformamide) is then added to the dried residue of [18F]fluoride and counterion.
-l - However, there still exists α need for efficient [18F]fluoride processing methodologies which allow rapid, efficient trapping and elution of [18F]fluoride from target water. Additionally, there is a need for such methodologies which are amenable to automation to facilitate improved preparation of radiopharmaceuticals in the clinical setting.
Accordingly, the present invention provides a method for preparing an [18F]fluoride solution which comprises: (i) contacting a solution of [18F]fluoride in water with a solid-support bound Cryptand of formula (I)
(I)
Figure imgf000003_0001
at a pH of less than 5 so as to form a Cryptand-[18F]fluoride complex of formula
18P
Figure imgf000003_0002
(ii) removal of excess water from the Cryptand-[18F]fluoride complex of formula (II); (iii) washing the Cryptand-[18F]fluoride complex of formula (II) with a solution of base, suitably a base having a pKa of at least 9 , so as to release the [18F]fluoride into solution.
In formula (I), the Solid Support may be any suitable solid-phase support which is insoluble in any solvents to be used in the method but to which the Linker and/or Cryptand may be covalently bound. Examples of suitable Solid Support include polymers such as polystyrene (which may be block grafted, for example with polyethylene glycol), polyacrylamide, or polypropylene, or glass or silicon coated with such a polymer. The Solid Support may take the form of small discrete particles such as beads or pins, or as coatings on a particle, for example, of glass or silicon, or a coating on the inner surface of a cartridge or microfabricated device.
In formula (I), the Linker is a Ci-so hydrocarbyl group optionally further including 1 to 10 heteroatoms such as oxygen or nitrogen. Suitable Linker groups include alkyl, alkenyl, αlkynyl chains, aromatic, polyaromatic, and heteroaromatic rings (for example, triazoles), and polymers comprising ethyleneglycol, amino acid, or carbohydrate subunits any of which may be optionally substituted for example with one or more ether, thiooether, sulphonamide, or amide functionality.
The compounds of formula (I) may be pre-conditioned by treatment with an acid solution to form a protonated derivative, or may be non-conditioned.
As used herein, the term "Cryptand" means a bi- or poly-cyclic multidentate ligand for the fluoride anion. Suitable Cryptands for binding anions such as fluoride have been reviewed in J.W. Steed, J. L Atwood in Supramolecular Chemistry (Wiley, New York, 2000), ppl98-249; Supramolecular Chemistry of Anions, Eds. A Bianchi, K Bowmann- James, E. Garcia-Espana (Wiley-VCH, New York, 1997), and P.D. Beer, PA Gale, Angew.Chem. 2001, 113, 502; Angew. Chem. Int. Ed. 2001, 40, 486.
Suitable Cryptands used herein include those of formula (C):
Figure imgf000004_0001
wherein:
Rl and R2 are independently selected from
Figure imgf000005_0001
R3, R4, and R5 are independently selected from:
Figure imgf000005_0002
Preferred Cryptands useful in the invention may be selected from:
Figure imgf000005_0003
or may be chosen to have desirable properties such as a high binding constant for fluoride, high stability of the fluoride bound complex and high fluoride selectivity over other anions. In the compounds of formula (I), the Cryptand is attached to a Linker group. The point of attachment may be a nitrogen or carbon atom in the Cryptand. Thus the point of attachment to the Linker "L" may be in group Rl or R2:
Figure imgf000006_0001
or in R3, R4, or R5:
Figure imgf000006_0002
The method of the invention may be performed by contacting the solid-support bound Cryptand of formula (I) with the solution of [18F]fluoride in water in a container and then separating the resulting solid-phase Cryptand-[18F]fluoride complex of formula (II) by filtration. Alternatively, and particularly suitably when the solid-support bound Cryptand of formula (I) is used within an automated apparatus, the solid-support bound Cryptand of formula (I) may be contained in a vessel either as discrete particles or as a coating through which the solution of [18FJfI uoride in water is passed. The solution of [18F]fluoride in water may be passed through the vessel containing solid- support bound Cryptand of formula (I) as a continuous flow, for example at a flow rate of from O.lml/min to lOOml/min, or in batches, so as to permit sufficient residence time on the solid-phase for the fluoride complexation to occur. As would be understood by the person skilled in the art, the solid-support bound Cryptand of formula (I) may be held in any suitable vessel such as a plastic or metal column, cartridge, or syringe barrel. The fluoride complexation is conveniently performed at ambient temperature, but use of non-extreme elevated temperature (for example up to 120°C, but preferably up to 80°C) can increase efficiency of the fluoride complexation.
Step (iii) of the process ie. washing the Cryptand-[18F]fluoride complex of formula (II) with a solution of base, suitably a base having a pKa of at least 9, so as to release the [18F]fluoride into solution is suitably effected in a similar manner to steps described above, the solid-support facilitating separation ofthe [18F]fluoride in solution. The base is suitably selected from a potassium salt (such as potassium carbonate, potassium bicarbonate, or potassium sulphate) optionally in the presence of a phase transfer catalyst such as Kryptofix; a tetraalkylammonium salt (such as tetraalkylammonium carbonate, tetralkylammonium bicarbonate, or tetraalkylammonium sulphate); a phosphonium salt (such as phosphonium carbonate, phosphonium bicarbonate, or phosphonium sulphate); a cesium salt (such as cesium carbonate, cesium bicarbonate, or cesium sulphate); and an imidazolium salt (such as imidazolium carbonate, imidazolium bicarbonate, or imidazolium sulphate) and is provided in a solution comprising organic solvent (suitably selected from acetonitrile, dimethylformamide, dimethylsulfoxide, tetrahydrofuran, dioxan, 1,2-dimethoxyethane, sulfolane or N- methylpyrrolidinone or a mixture of any thereof), water, or an organic solvent containing water. Suitably, the solution is formed in a dry organic solvent (i.e. containing less than lOOOppm water) , or an organic solvent containing water at a level which is tolerated in the subsequent radiofluoridation reaction, for example lOOOppm to 50,000ppm water, preferably 1000 to 15,000 ppm, more preferably 2000ppm to
7000ppm, suitably 2500ppm to 5000ppm, as is taught in WO 2006/054098. In this way, a further drying step before radiofluoridation may be avoided. In one aspect of the invention, step (iii) is performed using a small volume of base solution, such as 400μl or less, preferably 50μl or less, and more preferably 1 to lOμl. The [18F]fluoride solution is then obtained in highly concentrated form which is advantageous as the volume of water present is correspondingly low which means the customary step of drying the [18F]fluorϊde solution before performing a radiofluoridation reaction can be shorter or avoided altogether. Also, this aspect of the invention makes the method amenable to automation, and particularly in a smaller reaction vessel such as a miniaturised device.
An [18F]fluorϊde solution produced by the method of the invention may then be used in radiosynthetic processes, to perform nucleophilic [18F]fluoridation of a Vector.
As used herein, the term "Vector" means a biomolecule suitable for radiolabelling to form a radiopharmaceutical, such as a peptide, protein, hormone, polysaccaride, oligonucleotide, antibody fragment, cell, bacterium, virus, or small drug-like molecule.
The reaction of a Vector with an [18F]-fluoride solution produced by the method of the invention may be effected at an elevated temperature, for example up to 200°C or at non-extreme temperature, such as 10°C to 50°C, and most preferably at ambient temperature. The temperature and other conditions for radiofluoridation being selected according to the exact reaction being performed, nature of reaction vessel, solvents etc as would be apparent to a person skilled in the art.
Following [18F]-fluoridation, a purification step may be required which may comprise, for example, removal of excess [18F]-fluoride, removal of solvent, and/or separation from unreacted Vector. Excess [18F]-fluoride may be removed by conventional techniques such as ion-exchange chromatography (for example using BIO-RAD AG 1- X8 or Waters QMA) or solid-phase extraction (for example, using alumina). Excess solvents may be removed by conventional techniques such as evaporation at elevated temperature in vacuo or by passing a stream of inert gas (for example, nitrogen or argon) overthe solution. Alternatively, the [18F]-fluoridated Vector may be trapped on a solid-phase, for example a cartridge of reverse-phase absorbant for example a C5-18 derivatized silica, whilst the unwanted excess reagents and by-products are eluted, and then the [18F]-fluoridated Vector may be eluted from the solid-phase in purified form.
Selection and synthesis of a Solid Support and/or Linker in a compound of formula (I) may be effected by conventional techniques of solid phase chemistry, for example as described in Florencio Zaragoza Dorwald "Organic Synthesis on Solid Phase; Supports, Linker, Reactions", Wiley-VCH (2000).
Compounds of formula (I) may be prepared by reacting a compound of formula (III):
R" LINKER' CRYPTAND
with a compound of formula
IV
Solid Support — R (IV)
wherein the Solid Support and Cryptand are as defined above, Linker' is a portion of the Linker as defined above, and R111 and Rιv are reactive groups capable of covalent bonding to eachother so as to complete formation of the Linker. Suitably, one of R111 and Rιv is an amine and the other is a carboxylic acid or an activated carboxylic ester, isocyanate or isothiocyanate such that the compounds of formulae (III) and (IV) may be joined by simple amide forming reaction. Suitable activated carboxylic esters include the N-hydroxysuccinimidyl and N-hydroxysulfosuccinimidyl esters:
Figure imgf000009_0001
Alternatively one of R111 and Rιv may be a thiol and the other a group reactive towards a thiol, such as a maleimide or an a-halocarbonyl.
As would be apparent to the person skilled in the art, it may also be desirable for the Cryptαnd in the Compound of formula (III) to have protection groups on any exposed functional groups e.g. amino groups to prevent or reduce side-reactions during conversion to a Compound of formula (I). In these cases the protection group will be chosen from those commonly used for the functional group in question e.g tert- butylcarbamate for an amine. Other suitable protecting groups may be found in Protecting Groups in Organic Synthesis, Theodora W. Greene and Peter G. M. Wuts, published by John Wiley & Sons Inc. which further describes methods for incorporating and removing such protecting groups.
Certain compounds of formula (I) may be prepared by reacting a compound of formula
(III) wherein R111 is either an amino or carboxylic acid group with a compound of formula
(IV) wherein Rιv is either a carboxylic acid or amine group respectively. In these cases a compound of formula (III) may be coupled with a compound of formula (IV) optionally using in situ activating agents such as 2-(lH-benzotriazole-l-yl)-l, 1,3,3- tetramethyluronium hexafluorophosphate (HBTU) or N-[(dimethylamino)-lH-l,2,3- triazolo[4,5-b]pyridin-l-ylmethylene]-N-methylmethanamonium hexafluorophosphate N-oxide (HATU). Standard conditions will be used e.g. dimethylformamide (DMF) solution and a base e.g. triethylamine or diisopropylethylamine. Alternatively where Rιv in the compound of formula (IV) is a thiol group, this may be reacted with a compound (III) in which R111 is a thiol reactive group such as a maleimide or an a-halocarbonyl. This reaction may be performed in a pH buffered solution or an organic solvent. The product compound having the formula (II) might be purified by preparative high performance liquid chromatography.
The Cryptands may be synthesised as described in US20040267009 Al, Bernard Dietrich, Jean-Marie Lehn, Jean Guilhem and Claudine Pascard, Tetrehedron Letters, 1989, Vol. 30, No. 31, pp 4125-4128, Paul H. Smith et al, J. Org. Chem. , 1993, 58, 7939- 7941, Jonathan W. Steed et al, 2004, Journal of the American Chemical Society, 126, 12395-12402, Bing-guang Zhang et al, Chem. Comm., 2004, 2206-2207.
The synthesis of a Compound of formula (III) may be achieved as described in the above references for the underivatized Cryptands with modifications to the starting materials or by subsequent chemistry, for example, by alkylation of a secondary amine group of the Cryptαnd as illustrated in the Examples below. Compounds of formula (III) may also be prepared as shown in Schemes 2 to 5 in which L and R'" are as defined above for the Compound of formula (III).
Scheme 2
Figure imgf000011_0001
Scheme 3
Figure imgf000011_0002
Scheme 4
Figure imgf000011_0003
Scheme 5
Figure imgf000012_0001
Certain solid-support bound cryptands are novel. Therefore, as a further aspect of the invention, there is provided a compound of formula (I):
(I)
Figure imgf000012_0002
wherein the Solid Support and Linker are as defined above, and the Cryptand is of formula (C):
R1
R3 R4 R5 (C)
R2
wherein:
Rl and R2 are independently selected from
Figure imgf000013_0001
R3, R4, and R5 are independently selected from:
Figure imgf000013_0002
More preferably in this aspect of the invention, the Cryptand is selected from:
Figure imgf000013_0003
Preferred compounds of formula (III) used to prepare the compounds of formula include:
Figure imgf000014_0001
wherein L is α Linker' as defined above, and R111 is a reactive group as defined above, and is preferably selected from amine, carboxylic acid, activated carboxylic ester, isocyanate, isothiocyanate, thiol, maleimide, or a-halocarbonyl.
More preferred compounds of formula (III) used to prepare the compounds of formula (I) include:
Figure imgf000014_0002
wherein L is a Linker' as defined above, and R111 is a reactive group as defined above, and is preferably selected from amine, carboxylic acid, activated carboxylic ester, isocyanate, isothiocyanate, thiol, maleimide, or a-halocarbonyl.
According to a further aspect of the invention there is provided an apparatus for preparation of an [18F]fluoride solution by a method as described above. Therefore, there is provided an apparatus for preparation of an [18F]fluoride solution which comprises:
(i) a vessel containing a solid-support bound Cryptand of formula (I) as defined above; (ii) means for contacting a solution of [18F]fluoride in water with said solid-support bound Cryptand of formula (I) so as to form a Cryptand-[18F]fluoride complex of formula (II) as defined above;
(iii) means for removal of excess water from the Cryptand-[18F]fluoride complex of formula (II);
(iv) means for washing the Cryptand-[18F]fluoride complex of formula (II) with a solution of base, suitably a base having a pKa of at least 9, so as to release the [18F]fluoride into solution.
In a further embodiment, the apparatus forms part of, or is in fluid communication with, an automated radiosynthesis apparatus such that following preparation of the [18F]fluoride solution by a method of the invention, the [18F]fluoride solution is used in an [18F]fluoridation reaction. In one embodiment, the apparatus is a microfabricated device- either dedicated to preparation of an [18F]fluoride solution or further incorporating means to effect a radiofluoridation reaction.
In use of the apparatus, the solid-support bound Cryptand of formula (I), would be contacted with a solution of [18F]fluoride in water using methods described above to form the corresponding compound of formula (II) and then washed with a solution of base, suitably a base having a pKa of at least 9 so as to release the [18F]fluoride into solution.
Reviews of methods for construction of microfabricated devices and their application inter olio in synthetic chemistry, may be found in DeWitt, (1999) "Microreactors for Chemical Synthesis", Current Opinion in Chemical Biology, 3:350-6; Haswell, Middleton et al (2001) "The Application of Microreactors to Synthetic Chemistry", Chemical Communications: 391-8; Haswell and Skelton (2000) "Chemical and Biochemical
Microreactors", Trends in Analytical Chemistry 19(6), 389-395; and Jensen (2001) "Microreaction Engineering- Is Small Better?" Chemical Engineering Science, 56:293- 303. Suitable microfabricated devices for performing the methods of the invention have a contained network of microchannels or capillaries having an internal diameter of typically 10-300μm, more typically 50-300μm. The network of microchannels or capillaries may be etched or otherwise machined on the surface of a substrate, suitably made of glass or silicon. Alternatively, the microchannels may be created using polymers (for example PEEK plastic, cycloolefin copolymer, polydimethylsiloxane,
SU8 (an epoxy based photoresist), epoxy resin, or polymethylmethacrylate) which may be poured over a master (usually glass), allowed to cure and then peeled off, or are fabricated by injection moulding, hot embossing, casting, lithography, or machining.
The microchannels or capillaries may be sealed through bonding of a cover plate, suitably made from a metal (for example, gold or silver) or , more commonly, glass, creating a contained network capable of manipulating picolitre volumes of liquid or gas. The sealing method used depends on the materials selected and may be selected from thermal bonding (for glass chips), anodic bonding (for silicon chips), and for polymer chips the sealing method may be selected from clamping, gluing, application of heat and pressure, and natural adhesion. Flow capacity could be increased further, for example, by stacking multiple devices. These devices are designed to be used either with micro syringe pumps (available from Kloehen Limited, Las Vegas, USA) or under electroosmotic flow using fused silica capillaries for interfacing with reagents and analytical systems (such as ultraviolet (UV), capillary electrophoresis (CE), capillary electrochromatography (CEC), electrochemical, refractive index, and radioactivity detectors).
Where the vessel is a microchannel in a microfabricated device, it may be coated with a solid-support bound Cryptand of formula (I) by conventional methods, for example analogous to those described in WO2005/061110. Surface modification of poluethylene is reviewed in the book Advances in Polymer Science (Springer Berlin / Heidelberg ISSN 0065-3195 (Print) 1436-5030 (Online) Volume 169 DOI 10.1007/bl3502
Copyright 2004 ISBN 978-3-540-40769-0 DOI 10.1007/bl3524 Pages 231-294). Many of the techniques described will apply to other plastic materials. Where the microfabricated device is constructed from polytmethyl metacrylate) (PMMA), the surface of the PMMA may be amine functionalized as described in Anal. Chem., 72 (21), 5331 -5337, 2000. PMMA devices may also be functionalized as sulfhyril group as described in United States patent application 20050101006. Photografting allows the introduction of surface functional groups to a range of polymeric materials such as polycarbonates, PMMA, polydimethylsiloxane and polyolefins as described in Rohr, T., Ogletree, F.D., Svec, F., Frechet, J. M., "Surface Functionalization of Thermoplastic Polymers for the Fabrication of Microfluidic Devices by Photoinitiated Grafting," Adv. Funct. Mater. 2003, 13, 264-70. In addition, the reactive surface area may be increased by using chemically grafted three dimentional monoliths which can be included in a microf abdicated device as described in Rohr, T., Ogletree, F.D., Svec, F., Frechet, J.M., "Photografting and the Control of Surface Chemistry in Three-Dimensional Porous Polymer Monoliths," Macromolecules 2003, 36, 1677-84 and Stachowiak, T.B., Rohr, T., Hilder, E.F., Peterson, D.S., Yi, M., Svec, F., Frechet, J. M., "Fabrication of Porous Polymer Monoliths Covalently Attached to the Walls of Channels in Plastic Microdevices," Electrophoresis 2003, 24, 3689-93. Furthermore, the microfabricated device may also contain dual functionality where for example, in addition to the covalently bound cryptand, there may be an additional reagent e.g. solid supported substrate or chemical scavenger. Dual function devices are described in Peterson, D.S., Rohr, T., Svec, F., Frechet, J. M., "Dual-Function Microanalytical Device by In Situ Photolithographic Grafting of Porous Polymer Monolith: Integrating Solid- Phase Extraction and Enzymatic Digestion for Peptide Mass Mapping," Anal. Chem. 2003, 75, 5328-35.
The invention is illustrated by way of the following examples, in which these abbreviations are used:
Et3l\l : triethylamine
RT. : room temperature
MeOH : methanol
(t) BOC : (tertiary) butoxycarbonyl L : litre mL imillilitre hr(s) : hour(s) THF :tetrahydrofuran HPLC : high performance liquid chromatography
DCM : dichloromethane
LCMS : liquid chromatography mass spectrometry
NMR : nuclear magnetic resonance
TFA : trifluoroacetic acid
MBq : Mega Bequerel
RCP : radiochemical purity
Examples
Example 1: Synthesis of compound 4
Figure imgf000018_0001
Example Ki) Synthesis of compound 1
A IL 3-neck round-bottom flask equipped with a mechanical stirrer was charged with 16.7 mLof 98% tripropylamine and 0.33Lof99% isopropanol, and cooled to -78° C in a dry ice-isopropanol bath. To this mixture, solutions of 15.0 g 40% aqueous glyoxal (0.103 mole), diluted to 83 mL with isopropanol, and 10.0 g (0.0.683 moles) of 96% tris- (2-aminoethyl)amine (tren), diluted to 83 mL, were simultaneously added over a period of 2 hrs with vigorous stirring. (Initial concentration of glyoxal=1.24 M; Initial concentration of tren=0. 82 M). Then the reaction mixture was allowed to warm up overnight and briefly warmed up to 60° C. to ensure that the formation of compound 2 was complete. It was cooled to room temperature while nitrogen gas was blown over its surface. The solvent was removed under vacuum and chloroform (250 mL) was added. The resulting slurry was filtered through sand and concentrated under vacuum to give an orange solid (5.2 g, 43%).
Example l(ii) Synthesis of compound 2
Compound 1 (4 g, 11.2 mmol) was dissolved in methanol ((150 mL) and was cooled in an ice/water bath. Sodium borohydride (8 g, 208 mmol) was added portion wise over 30 minutes. The mixture was left to rise to room temperature with stiffing over 16 hours. The solution was concentrated to dryness under vacuum to give an off white solid. The solid was dissolved in water (100 mL) and was heated to 600C for half an hour during which time an oily material formed in the mixture. THF (100 mL) was added and the organic layer was separated. The aqueous layer was extracted again with THF (100 mL). The combined extracts were filtered through a phase separator cartridge and were concentrated to dryness under vacuum. The oily solids were re-dissolved in THF (20 mL) and water (15 mL) was added. The solution was concentrated slowly until a white solid crystallized which was collected by filtration, washed with ice cold water and dried under high vacuum (1.6 g, 38%).
Example l(iii) Synthesis of compound 3
Compound 2 (0.1 g, 0.270 mmol) was dissolved in dry DMF (5 mL) and potassium carbonate added (1.1 eq.0.297 mmol, 0.041 g). The alkyl bromide (1.1 eq.0.297 mmol, 81.7 mg) was added portion wise following the reaction by H PLC-mass spectrometry by taking approximately 0.1 mL volume from the reaction and diluting with 1:1 0.1% formic acid in wateπacetonitrile (10 mL). The reaction was stirred at room temperature for 16 hours. A further 0.25 equivalents of the alkyl bromide was added and the reaction stirred for a further 16 hours. The reaction mixture was concentrated to dryness under vacuum. This was used in the next step without further purification.
Example l(iv) Synthesis of compound 4 Crude compound 3 was dissolved in dry DMF (20 mL) and pyridine (2 mL) was added followed by di-tert-butylcarbonate (1 g, 4.58 mmol, 17 eq.). The mixture was heated at 70 0C under nitrogen for 16 hours. The crude product was analysed by thin layer chromatography (silica gel plates eluting with 10% methanol/DCM) and by LCMS. Thin layer chromatography showed two major spots having Rf values of 0.2 and 0.5 and some minor spots. The mixture was purified by flash column chromatography on silca gel eluting with 100% petrol 40-60 to 100% ethyl acetate. The second major peak was shown to be the desired penta-BOC product by NMR and LCMS (50 mg).
Example 2
Figure imgf000020_0001
Example 2(i) Synthesis of compound 5
Compound 2 (0.1 g, 0.270 mmol) was dissolved in dry DMF (2 mL) and a solution of the alkyl bromide (1.1 eq. 0.297 mmol, 81.07 mg) in dry DMF (1 mL) was added over 5 minutes. The solution was stirred at room temperature for 16 hours. The DMF was removed under reduced pressure and white solids dissolved in an minimum volume of water/methanol (1:1). Preparative HPLC (Phenomenex luna C18(2) 150x21.2, acetonitrile/water 5% to 70% over 10 minutes) gave a major peak having tr of 8-8.5 minutes which was freeze dried giving an white solid (15 mg). NMR and LCMS confirmed the structure.
Example 2(ii) Fluoride binding studies with [19F]-fluoride
Compound 5 (1 mg) in water (0.1 mL) acidified to pH 1 with IN HCI and an aqueous solution of potassium fluoride (0.1-1 eq) was added at RT. The solutions were analysed by reversed phase HPLC (l%TFA/water, 1%TFA MeCN gradient on Luna C5 150x4.6 mm, detecting at 254 nm). Example 2(ιιι) Fluoride radiolabellinq of compound 5 with [18F]-fluorιde
Figure imgf000021_0001
Compound 5
IM HCI (4.5μl_, 4.5μmol) was added to compound 5 (0.1 mg, 180 nmol) in 50:50 methanol / water (0.2 ml_). This acidified solution was added directly to a glass vial containing [18F]fluorιde (98 MBq)ιn target water (0.05 mL) and left at room temperature for 20 minutes. The reaction was analayzed by reverse phase HPLC (solvent A = 0.1% TFA in water; Solvent B = 0.1% TFA in MeCN, Luna C5 150x4.6 mm, detecting at 254 nm; Gradient: 0 to 3 minutes (2% B), 3-10 minutes (2 to 70% B), 10 to 13 minutes (70% B); 13 to 16 minutes (70 to 2% B), 16 to 21 minutes (2% B); flow rate ImL / minute. [18F]-5 has a retention time of 10.1 minutes. [18F]-5 was purified using the same HPLC method with a decay corrected isolated yield of 64%. Purified [18F]-5 is stable (>95%RCP) in an acidic solution (pH < 3).
Increasing the pH [18F]-5 solution to pH 7 results in the removal of more than 70% of the [18F]-fluorιde from the cryptand as measured by HPLC peak instensity.
HPLC Conditions:
0-3mιns 2%(B)
3-lOmιns 2-70%(B)
10-13mιns 70%(B)
13-16mιns 70-2%(B)
16-21mιns 2%(B)
Column Luna C5 150 x 4.6 mm
Eluent Solvent A: 0.1% TFA in water; Solvent B: 0.1% TFA in acetonitrile
Pump speed lmL/min,
Wavelength 254nm Example 3- synthesis of a resin bead-bound solid supported cryptand
Figure imgf000022_0001
Compound 2 and a base e.g. potassium carbonate are dissolved in dry DMF (2 mL) and is added to a suspension of (chloromethyl)polystyrene resin (e.g. Merrifield's peptide resin available from Sigma-Aldrich) in dry DMF (1 mL) was added over 5 minutes. The mixture is agitated at room temperature or elevated temperature until the free cryptand starting material is consumed (determined by LCMS). The DMF was removed by filtration and the resin washed a number of times with one or more organic solvents e.g. methanol, dicloromethane or dimethylformamide. The final resin is characterized by elemental analysis.
Example 2- synthesis of a resin bead-bound solid supported cryptand
Figure imgf000023_0001
NaOH, Methanol DMF,
Figure imgf000023_0002
Figure imgf000023_0003
TFA, DCM
Figure imgf000023_0004
Compound 5 is treated with an excess of tBOC anhydride to give the corresponding penta-BOC protected species. Saponification of the methyl ester to give the free acid, followed by amide bond formation with an amino-functionalized resin (e.g. (aminomethyl)polystyrene resin available from Sigma-Aldrich) using a coupling reagent (e.g. HATU) gives the solid-supported BOC protected cryptand. Finally, BOC de- protection using trifluofoacetic acid gives the desired solid-supported cryptand. This is characterized by NMR and elemental analysis.

Claims

Claims
1. A method for preparing an [18FJfI uoride solution which comprises: (i) contacting a solution of [18F]fluoride in water with a solid-support bound Cryptand of formula (I)
(I)
Figure imgf000024_0002
at a pH of less than 5 so as to form a Cryptand-[18F]fluoride complex of formula
18P
Figure imgf000024_0003
(ii) removal of excess water from the Cryptand-[18F]fluoride complex of formula (II); (iii) washing the Cryptand-[18F]fluoride complex of formula (II) with a solution of base , suitably a base having a pKa of at least 9 , so as to release the [18F]fluoride into solution.
2. A method according to claim 1 wherein the Cryptand is of formula (C):
Figure imgf000024_0001
wherein:
Rl and R2 are independently selected from
Figure imgf000025_0001
R3, R4, and R5 are independently selected from:
Figure imgf000025_0002
3. A method according to claim 1 or 2 wherein the Cryptand is selected from
Figure imgf000025_0003
4. A method according to any one of claims 1 to 3 wherein step (iii) is performed using a solution of base selected from: a potassium salt optionally in the presence of a phase transfer catalyst ; a tetraalkylammonium salt; a phosphonium salt; a cesium salt; and an imidazolium salt provided in a solution comprising organic solvent selected from αcetonitrile, dimethylformαmide, dimethylsulfoxide, tetrαhydrofurαn, dioxαn, 1,2- dimethoxyethαne, sulfolαne or N-methylpyrrolidinone or α mixture of any thereof , water, or an organic solvent as hereinbefore defined further containing water.
5. A method according to any one of claims 1 to 4 wherein step (iii) is performed using a solution of potassium carbonate and Kryptofix in acetonitrile optionally containing water.
6. A method according to any one of claims 1 to 5 wherein step (iii) is performed using a small volume of base solution, such as 400μl or less, preferably 50μl or less, and more preferably 1 to lOμl.
7. A [18F]radiofluoridation method comprising a method according to any one of claims 1 to 6 followed by reaction of the resultant [18F]fluoride solution with a Vector.
8. A compound of formula (I):
(I)
Figure imgf000026_0002
wherein the Cryptand is of formula (C):
Figure imgf000026_0001
wherein:
Rl and R2 are independently selected from
Figure imgf000027_0001
R3, R4, and R5 are independently selected from:
Figure imgf000027_0002
9. A compound of formula (I) according to claim 8 wherein the Cryptand is selected from
Figure imgf000027_0003
10. An apparatus for preparation of an [18F]fluoride solution which comprises:
(i) a vessel containing a solid-support bound Cryptand of formula (I) as defined in any one of claims I to 3; (ii) means for contacting a solution of [18F]fluoride in water with said solid-support bound Cryptand of formula (I) so as to form a Cryptand-[18F]fluoride complex of formula (II) as defined in any one of claims 1 to 3;
(iii) means for removal of excess water from the Cryptand-[18F]fluoride complex of formula (II);
(iv) means for washing the Cryptand-[18F]fluoride complex of formula (II) with a solution of base, suitably a base having a pKa of at least 9, so as to release the [18F]fluoride into solution.
11. Apparatus according to claim 10 which is a microfabricated device.
PCT/EP2008/068155 2008-01-03 2008-12-22 Fluoride processing method WO2009083530A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2010541049A JP5705547B2 (en) 2008-01-03 2008-12-22 Method and apparatus for adjusting fluoride ion solution
MX2010007398A MX2010007398A (en) 2008-01-03 2008-12-22 Fluoride processing method.
US12/810,893 US8980221B2 (en) 2008-01-03 2008-12-22 Fluoride processing method
RU2010126591/04A RU2475448C2 (en) 2008-01-03 2008-12-22 Method of treating fluoride
CN200880123900.8A CN102026913B (en) 2008-01-03 2008-12-22 fluoride processing method
EP08868276A EP2238074A2 (en) 2008-01-03 2008-12-22 Fluoride processing method
AU2008342628A AU2008342628B2 (en) 2008-01-03 2008-12-22 Fluoride processing method
CA2710799A CA2710799C (en) 2008-01-03 2008-12-22 Fluoride processing method
BRPI0821681-9A BRPI0821681A2 (en) 2008-01-03 2008-12-22 Method for preparing a fluoride solution and for conducting radio fluoridation, compound and apparatus for preparing a fluoride solution.
US14/659,414 US20150191477A1 (en) 2008-01-03 2015-03-16 Fluoride Processing Method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1869108P 2008-01-03 2008-01-03
US61/018,691 2008-01-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/810,893 A-371-Of-International US8980221B2 (en) 2008-01-03 2008-12-22 Fluoride processing method
US14/659,414 Division US20150191477A1 (en) 2008-01-03 2015-03-16 Fluoride Processing Method

Publications (2)

Publication Number Publication Date
WO2009083530A2 true WO2009083530A2 (en) 2009-07-09
WO2009083530A3 WO2009083530A3 (en) 2009-10-29

Family

ID=40612964

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/068155 WO2009083530A2 (en) 2008-01-03 2008-12-22 Fluoride processing method

Country Status (11)

Country Link
US (2) US8980221B2 (en)
EP (1) EP2238074A2 (en)
JP (1) JP5705547B2 (en)
KR (1) KR101538192B1 (en)
CN (1) CN102026913B (en)
AU (1) AU2008342628B2 (en)
BR (1) BRPI0821681A2 (en)
CA (1) CA2710799C (en)
MX (1) MX2010007398A (en)
RU (1) RU2475448C2 (en)
WO (1) WO2009083530A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012089594A1 (en) * 2010-12-29 2012-07-05 Ge Healthcare Limited Eluent solution
US20120329968A1 (en) * 2010-02-12 2012-12-27 Niigata University Method for producing 18f-labeled compound and high molecular compound to be used in the method
WO2013003530A1 (en) 2011-06-30 2013-01-03 General Electric Company Devices and methods for reducing radiolysis of radiolabeled compounds
US9005577B2 (en) 2008-04-30 2015-04-14 Siemens Medical Solutions Usa, Inc. Substrate based PET imaging agents

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6605034B2 (en) * 2014-11-07 2019-11-13 ザ アサン ファウンデーション Method for producing and purifying organic fluoride compound

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002157A1 (en) * 2001-06-29 2003-01-09 Amersham Plc Solid-phase nucleophilic fluorination
US20030075508A1 (en) * 2001-09-07 2003-04-24 Woodruff L. Andy Ion exchange cryptands covalently bound to substrates
WO2005097713A1 (en) * 2004-04-08 2005-10-20 Ge Healthcare Limited Fluoridation method
WO2008155339A2 (en) * 2007-06-20 2008-12-24 Ge Healthcare Limited Labelling methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2541666B1 (en) * 1983-02-25 1985-06-21 Rhone Poulenc Spec Chim DISMUTATION PROCESS FOR SILANES
US5425063A (en) * 1993-04-05 1995-06-13 Associated Universities, Inc. Method for selective recovery of PET-usable quantities of [18 F] fluoride and [13 N] nitrate/nitrite from a single irradiation of low-enriched [18 O] water
US5728843A (en) * 1993-10-04 1998-03-17 Wallace Technologies (2'-nitro-1'-imidazolyl)-2,3-isopropylidene-y-tosylbutanol, a precursor to 18 F!fluoroerythronitroimidazole PET imaging agent
RU2167812C2 (en) * 1999-07-27 2001-05-27 ОАО "Кирово-Чепецкий химический комбинат имени Б.П. Константинова" Method and reactor for producing carbonyl fluoride
GB2386032B (en) 2002-03-01 2005-08-24 Parc Technologies Ltd Method of estimating traffic data
US8595071B2 (en) 2003-06-30 2013-11-26 Google Inc. Using enhanced ad features to increase competition in online advertising
GB0329716D0 (en) * 2003-12-23 2004-01-28 Amersham Plc Radical trap
WO2006071470A2 (en) 2004-12-03 2006-07-06 California Institute Of Technology Microfluidic devices with chemical reaction circuits
GB0516564D0 (en) 2005-08-12 2005-09-21 Ge Healthcare Ltd Fluorination process
US7723322B2 (en) 2006-03-31 2010-05-25 The Regents Of The University Of California Fluoride carrier for positron emission tomography

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002157A1 (en) * 2001-06-29 2003-01-09 Amersham Plc Solid-phase nucleophilic fluorination
US20030075508A1 (en) * 2001-09-07 2003-04-24 Woodruff L. Andy Ion exchange cryptands covalently bound to substrates
WO2005097713A1 (en) * 2004-04-08 2005-10-20 Ge Healthcare Limited Fluoridation method
WO2008155339A2 (en) * 2007-06-20 2008-12-24 Ge Healthcare Limited Labelling methods

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
M. BASALLOTE, E. BLANCO, M. BLAZQUEZ, M. J. FERNANDEZ TRUJILO, R. LITRAN, M. ANGELES MANEZ, M. RAMIREZ DEL SOLAR: "Exploring the Properties and Optical Sensing Capability of Sol-Gel Materials Containing a Covalently Bonded Binucleating Cryptand" CHEM. MATER., vol. 15, 2003, pages 2025-2032, XP002530667 *
M. TOMOI, N. YANAI, S. SHIIKI, H. KAKIUCHI: "Phase Transfer Reactions catalyzed by Polymer Supported Crown Ethers" JOURNAL OF POLYMER SCIENCE, vol. 22, 1984, pages 911-926, XP002528820 *
S. REILLY, G.R.K. KHALSA, D.K. FORD, J.R. BRAINARD, B.P. HAY, P.H. SMITH: "Octaazacryptand Complexation of the Fluoride ion" INORGANIC CHEMISTRY, vol. 34, 1995, pages 569-575, XP002528821 *
See also references of EP2238074A2 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9005577B2 (en) 2008-04-30 2015-04-14 Siemens Medical Solutions Usa, Inc. Substrate based PET imaging agents
US10821196B2 (en) 2008-04-30 2020-11-03 Siemens Medical Solutions Usa, Inc. Substrate based PET imaging agents
US20120329968A1 (en) * 2010-02-12 2012-12-27 Niigata University Method for producing 18f-labeled compound and high molecular compound to be used in the method
US9073802B2 (en) * 2010-02-12 2015-07-07 Tokyo Institute Of Technology Method for producing 18F-labeled compound and high molecular compound to be used in the method
JP5835801B2 (en) * 2010-02-12 2015-12-24 国立大学法人東京工業大学 Method for producing 18F-labeled compound and polymer compound used in the method
KR101768926B1 (en) 2010-02-12 2017-08-17 도오쿄 인스티튜드 오브 테크놀로지 Method for producing 18f-labeled compound and high molecular compound to be used in the method
WO2012089594A1 (en) * 2010-12-29 2012-07-05 Ge Healthcare Limited Eluent solution
CN103270004A (en) * 2010-12-29 2013-08-28 通用电气健康护理有限公司 Eluent solution
JP2014508731A (en) * 2010-12-29 2014-04-10 ジーイー・ヘルスケア・リミテッド Elution solution
AU2011351550B2 (en) * 2010-12-29 2017-02-02 Ge Healthcare Limited Eluent solution
CN108218650A (en) * 2010-12-29 2018-06-29 通用电气健康护理有限公司 Elute solution
WO2013003530A1 (en) 2011-06-30 2013-01-03 General Electric Company Devices and methods for reducing radiolysis of radiolabeled compounds

Also Published As

Publication number Publication date
CA2710799A1 (en) 2009-07-09
US8980221B2 (en) 2015-03-17
AU2008342628A1 (en) 2009-07-09
RU2475448C2 (en) 2013-02-20
KR101538192B1 (en) 2015-07-20
RU2010126591A (en) 2012-02-10
CN102026913A (en) 2011-04-20
CN102026913B (en) 2014-10-22
AU2008342628B2 (en) 2014-05-01
CA2710799C (en) 2015-11-24
US20150191477A1 (en) 2015-07-09
KR20100116597A (en) 2010-11-01
EP2238074A2 (en) 2010-10-13
MX2010007398A (en) 2010-10-05
BRPI0821681A2 (en) 2015-06-16
JP2011512514A (en) 2011-04-21
JP5705547B2 (en) 2015-04-22
US20100285570A1 (en) 2010-11-11
WO2009083530A3 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
US20150191477A1 (en) Fluoride Processing Method
US9169284B2 (en) Use of microfabricated devices
Coenen et al. 18F-labelling innovations and their potential for clinical application
EP1572249B1 (en) Solid-phase fluorination of uracil
JP2012167109A (en) Purification method
Dallinger et al. Microwave-assisted scavenging of electrophiles utilizing polymer-supported sequestration reagents. Application to the synthesis of N3-acylated dihydropyrimidine libraries
AU2013204412A1 (en) Fluoride processing method
AU2009319229A1 (en) Radiofluorination
AU2008265184B2 (en) Labelling methods
US10087141B2 (en) Synthesis of [18F]-fluoroalkyl tosylate
CN110312704A (en) The manufacturing method of labeled with radioactive fluorine precursor compound and the compound labeled with radioactive fluorine using it
CN117049949A (en) 5- [ 18 F]Synthesis method of (2-fluoroalkoxy) cycloocta-1-ene
WO2023244274A2 (en) Composition of a lipophilic agent for solution phase synthesis of biomolecules
US7226661B2 (en) Synthesis of quinones and phenols on solid support

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880123900.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08868276

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2710799

Country of ref document: CA

Ref document number: 2008342628

Country of ref document: AU

Ref document number: 2010541049

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12810893

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 4758/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/007398

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008342628

Country of ref document: AU

Date of ref document: 20081222

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107017243

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2008868276

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008868276

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010126591

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0821681

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100630